PMID- 31467061
OWN - NLM
STAT- MEDLINE
DCOM- 20200205
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 134
IP  - 16
DP  - 2019 Oct 17
TI  - Prolonged survival with the early use of a novel extracorporeal photopheresis 
      regimen in patients with Sezary syndrome.
PG  - 1346-1350
LID - 10.1182/blood.2019000765 [doi]
AB  - Extracorporeal photopheresis (ECP) has demonstrated therapeutic benefit in 
      patients with Sezary syndrome (SS) and erythrodermic mycosis fungoides (e-MF). To 
      examine the efficacy of ECP in the modern era of novel therapies, we conducted a 
      retrospective analysis of 65 patients with a diagnosis of SS or e-MF with blood 
      involvement who were treated with ECP at our institute. Overall survival (OS), 
      time to next treatment (TTNT), and skin response rate (RR) were used as the study 
      end points to determine patient outcome. The median follow-up from diagnosis was 
      48 months (range 1-225 months), with a median predicted OS of 120 months. The 
      majority (88%) of patients commenced ECP at treatment lines 1 to 3, either as a 
      monotherapy or in conjunction with other systemic agents. The use of ECP 
      monotherapy resulted in a significantly longer median TTNT when compared with 
      interferon-alpha (P = .0067), histone deacetylase inhibitors (P = .0003), novel 
      immunotherapy agents (P = .028), low-dose methotrexate (P < .0001), and 
      chemotherapy (P < .0001). In particular, early commencement of ECP at treatment 
      lines 1 to 3 yielded a TTNT of 47 months. The results of our study support the 
      utilization of ECP for SS/e-MF, and we recommend that ECP should be considered as 
      early as possible in the treatment paradigm for these patients.
CI  - (c) 2019 by The American Society of Hematology.
FAU - Gao, Crystal
AU  - Gao C
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
AD  - Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, 
      Australia.
FAU - McCormack, Christopher
AU  - McCormack C
AD  - Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, 
      Australia.
AD  - Department of Dermatology, St Vincent's Hospital, Melbourne, Australia.
FAU - van der Weyden, Carrie
AU  - van der Weyden C
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
FAU - Goh, Michelle S
AU  - Goh MS
AD  - Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, 
      Australia.
AD  - Department of Dermatology, St Vincent's Hospital, Melbourne, Australia.
FAU - Campbell, Belinda A
AU  - Campbell BA
AD  - Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, 
      Australia.
FAU - Twigger, Robert
AU  - Twigger R
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
FAU - Buelens, Odette
AU  - Buelens O
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
FAU - Harrison, Simon J
AU  - Harrison SJ
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia; and.
FAU - Khoo, Christine
AU  - Khoo C
AD  - Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
FAU - Lade, Stephen
AU  - Lade S
AD  - Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
FAU - Prince, H Miles
AU  - Prince HM
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal 
      Melbourne Hospital, Melbourne, Australia.
AD  - Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia; and.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
CIN - Blood. 2019 Oct 17;134(16):1275-1277. PMID: 31698438
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Photopheresis/*methods
MH  - Retrospective Studies
MH  - Sezary Syndrome/mortality/*therapy
MH  - Skin Neoplasms/mortality/*therapy
EDAT- 2019/08/31 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/03/25 00:00 [received]
PHST- 2019/07/30 00:00 [accepted]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2019/08/31 06:00 [entrez]
AID - S0006-4971(20)74046-2 [pii]
AID - 10.1182/blood.2019000765 [doi]
PST - ppublish
SO  - Blood. 2019 Oct 17;134(16):1346-1350. doi: 10.1182/blood.2019000765.